LARP1 predict the prognosis for early-stage and AFP-normal hepatocellular carcinoma

Journal of Translational Medicine

Zhiliang Gao³  Liang Peng²  Peipei Wang²  Genlin Zhang²  Dongying Xie²  Shibin Xie²  Li Huang¹  Chan Xie³ 

[1] Department of nephrology, The Third affiliated hospital of Guangzhou medical university, Guangzhou, China;Department of Infectious Diseases, The Third Affiliated Hospital of Sun Yat-Sen University, 600# TianHe Road, Guangzhou 510630, Guangdong Province, China;Key Laboratory of Tropical Disease Control, Ministry of Education, Sun Yat-Sen University, Guangzhou, Guangdong Province, China

关键词: Prognosis;    AFP;    Hepatocellular carcinoma;    LARP1;   

Others  :  824817
DOI  :  10.1186/1479-5876-11-272

 received in 2013-06-26, accepted in 2013-10-24,  发布年份 2013

【 摘 要 】

Background

The La-related protein 1 (LARP1) has been found to be a RNA binding protein and was related to spermatogenesis, embryogenesis and cell-cycle progression. The aim of this study was to investigate the prognostic value of LARP1 in hepatocellular carcinoma (HCC).

Methods

LARP1 expression was examined in 15 HCC cell lines and 272 clinical specimens using real-time PCR, immunohistochemistry (IHC) and western blot analysis (WB). LARP1 expression was also studied in 6 paired HCC lesions and the adjacent non-cancerous tissue samples. Statistical analyses were applied to derive association between LARP1 expression scores and clinical characters as well as patient survival.

Results

mRNA and protein levels of LARP1 were higher in HCC cell lines and HCC lesions than in normal liver epithelial cells and the paired adjacent noncancerous tissues. LARP1 expression was correlated to survival time, vital status, tumor size and Child-Pugh score. Overall survival analysis showed HCC patients with high LARP1 expression level had lower survival rate (P < 0.01). Importantly, this correlation remained significant in patients with early-stage HCC or with normal serum AFP level.

Conclusions

LARP1 protein may represent a promising biomarker for predicting the prognosis of HCC, including in early-stage and AFP-normal patients.

【 授权许可】

   
2013 Xie et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

【 参考文献 】

• [1]Parkin DM, Bray F, Ferlay J, Pisani P: Global cancer statistics, 2002. CA Cancer J Clin 2005, 55:74-108.
• [2]Tandon P, Garcia-Tsao G: Prognostic indicators in hepatocellular carcinoma: a systematic review of 72 studies. Liver Int 2009, 29:502-510.
• [3]Ichihara K, Shimizu H, Taguchi O, Yamaguchi M, Inoue YH: A Drosophila orthologue of larp protein family is required for multiple processes in male meiosis. Cell Struct Funct 2007, 32:89-100.
• [4]Chauvet S, Maurel-Zaffran C, Miassod R, Jullien N, Pradel J, Aragnol D: dlarp, a new candidate Hox target in Drosophila whose orthologue in mouse is expressed at sites of epithelium/mesenchymal interactions. Dev Dyn 2000, 218:401-413.
• [5]Blagden SP, Gatt MK, Archambault V, Lada K, Ichihara K, Lilley KS, Inoue YH, Glover DM: Drosophila Larp associates with poly(A)-binding protein and is required for male fertility and syncytial embryo development. Dev Biol 2009, 334:186-197.
• [6]Burrows C, Abd Latip N, Lam SJ, Carpenter L, Sawicka K, Tzolovsky G, Gabra H, Bushell M, Glover DM, Willis AE, Blagden SP: The RNA binding protein Larp1 regulates cell division, apoptosis and cell migration. Nucleic Acids Res 2010, 38:5542-5553.
• [7]Xie C, Song LB, Wu JH, Li J, Yun JP, Lai JM, Xie DY, Lin BL, Yuan YF, Li M, Gao ZL: Upregulator of cell proliferation predicts poor prognosis in hepatocellular carcinoma and contributes to hepatocarcinogenesis by downregulating FOXO3a. PLoS One 2012, 7:e40607.
• [8]Nykamp K, Lee MH, Kimble J: C. elegans La-related protein, LARP-1, localizes to germline P bodies and attenuates Ras-MAPK signaling during oogenesis. RNA 2008, 14:1378-1389.
• [9]Bousquet-Antonelli C, Deragon JM: A comprehensive analysis of the La-motif protein superfamily. RNA 2009, 15:750-764.
• [10]Nagasue N: Liver resection for hepatocellular carcinoma: indications, techniques, complications, and prognostic factors. J Hepatobiliary Pancreat Surg 1998, 5:7-13.
• [11]Peng SY, Chen WJ, Lai PL, Jeng YM, Sheu JC, Hsu HC: High alpha-fetoprotein level correlates with high stage, early recurrence and poor prognosis of hepatocellular carcinoma: significance of hepatitis virus infection, age, p53 and beta-catenin mutations. Int J Cancer 2004, 112:44-50.
• [12]Trevisani F, D’Intino PE, Morselli-Labate AM, Mazzella G, Accogli E, Caraceni P, Domenicali M, De Notariis S, Roda E, Bernardi M: Serum alpha-fetoprotein for diagnosis of hepatocellular carcinoma in patients with chronic liver disease: influence of HBsAg and anti-HCV status. J Hepatol 2001, 34:570-575.
• [13]Llovet JM, Bruix J: Novel advancements in the management of hepatocellular carcinoma in 2008. J Hepatol 2008, 48(Suppl):20-37.
• [14]Bruix J, Sherman M, Llovet JM, Beaugrand M, Lencioni R, Burroughs AK, Christensen E, Pagliaro L, Colombo M, Rodés J: EASL Panel of Experts on HCC. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. J Hepatol 2001, 35:421-430.